Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.13.5493

Efficacy of Taxane-Based Regimens in a First-line Setting for Recurrent and/or Metastatic Chinese Patients with Esophageal Cancer  

Jiang, Chang (State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center)
Liao, Fang-Xin (State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center)
Rong, Yu-Ming (State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center)
Yang, Qiong (State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center)
Yin, Chen-Xi (State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center)
He, Wen-Zhuo (State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center)
Cai, Xiu-Yu (State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center)
Guo, Gui-Fang (State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center)
Qiu, Hui-Juan (State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center)
Chen, Xu-Xian (State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center)
Zhang, Bei (State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center)
Xia, Liang-Ping (State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.13, 2014 , pp. 5493-5498 More about this Journal
Abstract
Objective: To compare the efficacy of taxane-based regimens in the first line setting retrospectively in Chinese patients with recurrent and/or metastatic esophageal cancer. Methods: We analyzed 102 recurrent and/or metastatic esophageal cancer patients who received taxanes-based regimens in a first-line setting from January 2009 to December 2013. Sixteen (15.7%) patients were administered Nab-PTX based chemotherapy and 86 patients (84.3%) received paclitaxel (PTX) or docetaxel (DTX) based chemotherapy. Patients in the PTX/DTX group could be further divided into TP (71 patients) and TPF (15 patients) groups. Results: The objective response rate (ORR) of all patients was 20.6%, and the disease control rate (DCR) was 67.6%. The median overall survival (OS) was 10.5 months (95% CI 10.1-16.4) and the median progression-free survival (PFS) was 6.04 months (95% CI 5.09-7.91). The DCR was higher in the TPF group than the TP group (93.3% vs. 59.1%; p = 0.015 ). There were no significant differences in ORR, OS, and PFS among Nab-PTX, TPF and TP groups. Conclusions: The three regimens of Nab-PTX based, TP and TPF proved active in a first line setting of Chinese patients with recurrent and/or metastatic esophageal cancer, and should thus be regarded as alternative treatments.
Keywords
Esophageal cancer; docetaxel; paclitaxel; nanoparticle albumin; bound paclitaxel;
Citations & Related Records
Times Cited By KSCI : 4  (Citation Analysis)
연도 인용수 순위
1 Roth AD, Fazio N, Stupp R, et al. (2007). Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; epirubicin, cisplatin, fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol, 25, 3217-23.   DOI   ScienceOn
2 Shah MA, Jhawer M, Ilson DH, et al. (2011). Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol, 29, 868-74.   DOI   ScienceOn
3 Sparreboom A, Scripture CD, Trieu V, et al. (2005). Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in cremophor (Taxol). Clin Cancer Res, 11, 4136-43.   DOI   ScienceOn
4 Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. (2006). Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol, 24, 4991-7.   DOI   ScienceOn
5 Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. (2006). Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol, 24, 4991-7.   DOI   ScienceOn
6 Lu YF, Liu ZC, Li ZH, et al. (2014). Esophageal/gastric cancer screening in high-risk populations in Henan Province, China. Asian Pac J Cancer Prev, 15, 1419-22.   과학기술학회마을   DOI   ScienceOn
7 Ji FZ, Zhu WG, Yu CH, et al. (2013). A randomized controlled trial of intensity-modulated radiation therapy plus docetaxel and cisplatin versus simple intensity-modulated radiation therapy in II-III stage esophageal carcinoma. Chinese J Gastrointestinal Surgery, 16, 842-5.
8 Jie. H, Kang. S (2011). The epidemiology, current status of management, challenge and future strategy for esophageal cancer in China. China Oncology, 21, 501-4.
9 Jones SE, Erban J, Overmoyer B, et al. (2005). Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol, 23, 5542-51.   DOI   ScienceOn
10 Mizota A, Shitara K, Kondo C, et al. (2011). A retrospective comparison of docetaxel and paclitaxel for patients with advanced or recurrent esophageal cancer who previously received platinum-based chemotherapy. Oncology, 81, 237-42.   DOI   ScienceOn
11 Nakajima M, Kato H (2013). Treatment options for esophageal squamous cell carcinoma. Expert Opinion on Pharmacotherapy, 14, 1345-54.   DOI   ScienceOn
12 O'Shaughnessy J, Gradishar WJ, Bhar P, Iglesias J (2013). Nab-paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis. Breast Cancer Res Treat, 138, 829-37.   DOI
13 Park SH, Lee WK, Chung M, et al. (2006). Paclitaxel versus docetaxel for advanced gastric cancer: a randomized phase II trial in combination with infusional 5-fluorouracil. Anticancer Drugs, 17, 225-9.   DOI   ScienceOn
14 Gu M, Li SY, Huang XE, et al. (2012). A phase II study on continuous infusional paclitaxel and 5-Fu as first-line chemotherapy for patients with advanced esophageal cancer. Asian Pac J Cancer Prev, 13, 5587-91.   과학기술학회마을   DOI   ScienceOn
15 Hsu Y, Sood AK, Sorosky JI (2004). Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer: case-control analysis of toxicity. Am J Clin Oncol, 27, 14-8.   DOI   ScienceOn
16 Einzig AI, Neuberg D, Remick SC, et al. (1996). Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol, 13, 87-93.   DOI   ScienceOn
17 Esteban E, Gonzalez de Sande L, Fernandez Y, et al. (2003). Prospective randomised phase II study of docetaxel versus paclitaxel administered weekly in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. Ann Oncol, 14, 1640-7.   DOI   ScienceOn
18 Fujita Y, Hiramatsu M, Kawai M, et al. (2008). Evaluation of combined docetaxel and nedaplatin chemotherapy for recurrent esophageal cancer compared with conventional chemotherapy using cisplatin and 5-fluorouracil: a retrospective study. Dis Esophagus. 21, 496-501.   DOI   ScienceOn
19 Huang J, Cai RG, Meng PJ, et al. (2004). Phase II study of paclitaxel and cisplatin for advanced squamous-cell carcinoma of esophagus. Chinese J Oncol, 26, 753-5.
20 International Agency for Research on Cancer;GLOBOCAN 2012. Available from URL: http://www-dep.iarc.fr/CancerMondial.htm.
21 Ilson DH, Ajani J, Bhalla K, et al. (1998). Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol, 16, 1826-34.   DOI
22 Al-Hajeili M, Azmi AS, Choi M (2014). Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer. Onco Targets Ther, 7, 187-92.
23 Bang YJ, Van Cutsem E, Feyereislova A, et al. (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 376, 687-97.   DOI   ScienceOn
24 Ajani JA, Ilson DH, Daugherty K, et al. (1994). Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst, 86, 1086-91.   DOI   ScienceOn
25 Ajani JA, Fodor MB, Tjulandin SA, et al. (2005). Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol, 23, 5660-7.   DOI   ScienceOn
26 Burtness B, Gibson M, Egleston B, et al. (2009). Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer. Ann Oncol, 20, 1242-8.   DOI   ScienceOn
27 Desai N, Trieu V, Yao Z, et al. (2006). Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res, 12, 1317-24.   DOI   ScienceOn
28 Desai NP, Trieu V, Hwang LY, et al. (2008). Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anti-Cancer Grug, 19, 899-909.   DOI   ScienceOn
29 Wu S, Chen MY, Luo JC, Wei L, Chen Z (2012). Comparison between docetaxel plus cisplatin and cisplatin plus fluorouracil in the neoadjuvant chemoradiotherapy for local advanced esophageal squamous cell carcinoma. Chinese J Oncol, 34, 873-6.
30 Dubecz A, Solymosi N, Stadlhuber RJ, et al. (2014). Does the incidence of adenocarcinoma of the esophagus and gastric cardia continue to rise in the twenty-first century? a SEER Database analysis. J Gastrointest Surg, 18, 124-9.   DOI   ScienceOn
31 Vizcaino AP, Moreno V, Lambert R, Parkin DM (2002). Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer 99, 860-8.   DOI   ScienceOn
32 Zhang P, Xie CY, Wu SX (2007). Concurrent chemoradiation with paclitaxel and platinum for locally advanced esophageal cancer. Chinese J Oncol, 29, 773-7.
33 Wang T, Zhang SF, Wang L (2010). A 24-hour continuous infusion of paclitaxel in the treatment of advanced esophageal cancer. Natl Medical J China, 90, 1986-8.
34 Xing PY, Li JL, Wang Y, et al. (2013). Efficacy and safety of albumin-bound paclitaxel in treating recurrent advanced non-small-cell lung cancer. Chin J Cancer Res, 25, 200-5.
35 Zhang DS, Wang DS, Wang ZQ, et al. (2013). Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancreatic cancer. Cancer Chemother Pharmacol, 71, 1065-72.   DOI   ScienceOn
36 Zhang TR, Zhao T, Xu X, Gu XW, Pan YK (2010). Efficacy and side-effects of docetaxel combined with cisplatin on the treatment of local advanced esophageal cancer with concomitant radiation therapy. Chinese J Oncol, 32, 791-4.
37 Zhao J, He YT, Zheng RS, Zhang SW, Chen WQ (2012). Analysis of esophageal cancer time trends in China, 1989- 2008. Asian Pac J Cancer Prev, 13, 4613-7.   과학기술학회마을   DOI   ScienceOn
38 Shi Y, Qin R, Wang ZK, Dai GH (2013). Nanoparticle albumin-bound paclitaxel combined with cisplatin as the first-line treatment for metastatic esophageal squamous cell carcinoma. Onco Targets Ther, 6, 585-91.
39 Petrasch S, Welt A, Reinacher A, et al. (1998). Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer. Br J Cancer, 78, 511-4.   DOI
40 Thallinger CMR, Raderer M, Hejna M (2011). Esophageal Cancer: A Critical Evaluation of Systemic Second-Line Therapy. J Clin Oncol, 29, 4709-14.   DOI
41 Mirinezhad SK, Jangjoo AG, Seyednejad F, et al. (2014). Impact of tumor length on survival for patients with resected esophageal cancer. Asian Pac J Cancer Prev, 15, 691-4.   과학기술학회마을   DOI   ScienceOn
42 Von Hoff DD, Ervin T, Arena FP, et al. (2013). Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. New Engl. J Med, 369, 1691-703.